TABLE 3.

Proportions of participants achieving a serotype-specific cutoff antibody level at 4 weeks after the PCV7 booster according to whether MCC/Hib vaccine was given concomitantly

Serotype	Cutoff value (μg/ml)	MCC/Hib vaccine	No. of sera	No. above cutoff value	Proportion above cutoff value (95% CI)
4	≥0.35	Without	106	106	1.00 (0.97-1.00)
		With	91	91	1.00 (0.96-1.00)
	≥1.0	Without	106	104	0.98 (0.93-1.00)
		With	91	87	0.96 (0.89-0.99)
6B	≥0.35	Without	107	106	0.99 (0.95-1.00)
		With	91	88	0.97 (0.91-0.99)
	≥1.0	Without	107	103	0.96 (0.91-0.99)
		With	91	85	0.93 (0.86-0.98)
9V	≥0.35	Without	107	107	1.00 (0.97-1.00)
		With	90	90	1.00 (0.96-1.00)
	≥1.0	Without	107	103	0.96 (0.91-0.99)
		With	90	89	0.99 (0.94-1.00)
14	≥0.35	Without	107	107	1.00 (0.97-1.00)
		With	91	91	1.00 (0.96-1.00)
	≥1.0	Without	107	107	1.00 (0.97-1.00)
		With	91	90	0.99 (0.94-1.00)
18C	≥0.35	Without	106	105	0.99 (0.95-1.00)
		With	91	88	0.97 (0.91-0.99)
	≥1.0	Without	106	92	0.87 (0.79-0.93)
		With	91	72	0.79 (0.69-0.87)
19F	≥0.35	Without	107	106	0.99 (0.95-1.00)
		With	91	91	1.00 (0.96-1.00)
	≥1.0	Without	107	106	0.99 (0.95-1.00)
		With	91	90	0.99 (0.94-1.00)
23F	≥0.35	Without	107	105	0.98 (0.93-1.00)
		With	91	90	0.99 (0.94-1.00)
	≥1.0	Without	107	97	0.91 (0.83-0.95)
		With	91	88	0.97 (0.91-0.99)